Yesterday, at the ePharma Summit, I spoke on a panel with Marc Monseau of 
Johnson & Johnson and Fabio Gratton of Ignite Health about how drug firms can develop policies and procedures for their social media marketing efforts. It was an interesting session and we received lots of good questions from the audience, including the usual ones about navigating regulatory/legal hurdles.
Given this, it’s very interesting that Waggener Edstrom is holding an event on February 24 titled "Healthcare Communications in the Digital World: Mitigating the Risks in a Highly Regulated Environment." The event will feature Sanjay J. Koyani, Director of Web Communications at the U.S. Food and Drug Administration.
I’m not sure if Koyani will be revealing a lot of specifics about how the FDA will regulate digital and social media, but hopefully he can provide some clues about how the new Administration will handle these issues. However, it’s worth saying that I would be very surprised if Koyani did not say that the agency will continue to hew to its bedrock regulatory principles re: adverse event reporting, off-label promotion and fair balance.
To learn more about the event and to register, please click here.
Comment Preview